Want to Calculate Fair Value?
Enter Stock | Calculate Fair Value

Stock: CRL
Book Value Per Share: $65.04
EPS: $9.60
Diluted EPS TTM: $-0.61
Dividend Per Share: None
Dividend Yield: 0.00 %
Dividend Payout Ratio: 0%
Price To Sales Ratio TTM: 1.656
Price To Book Ratio: 2.085
PEG Ratio: 0.117
EV To EBITDA: 17.25
P/E Ratio: None
Forward P/E Ratio: 14.35
Ex Dividend Date: None
Dividend Date: None
Current Price: $149.45
Previous Close: $151.89
52 Week Low: $91.86
52 Week High: $254.15
Earning Date (within 30 days): N/A
50 Day MA: $132.19
200 Day MA: $172.45
Link to Yahoo (Financial): CRL
 
* Note: Prices are in Million (M) USD.
Description:
Charles River Laboratories (CRL) ▼
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
These criteria used Company’s Cash, EBITDA and Debt balance to determines its fair value:
Cash : $195 M
Debt : $2,240 M
EBITDA : $889 M
Net Debt (Debt - Cash): $2,046 M

Since Net Debt is covered by EBITDA within 3 years, 1 points assigned.
This criteria used industry in which company operates:
Sector: Healthcare
Industry: Diagnostics & Research

Based on industry, 3 points assigned.
This criteria used Company’s Price To Earning (P/E) Ratio to determines its fair value:
Forward PE Ratio: 15.57

Since Forward PE Ratio is between 15 - 20, 3 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Average Free Cash Flow: $231 M
Average Revenue: $2,012 M
Free Cash Flow to Revenue : 12 %

Since Free Cash Flow (FCF) to Revenue percentage is less than 15, 1 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $4,050 M
Revenue 4 Years Ago (2020-12-31): $2,924 M
Last 5 Years Average Revenue Growth: 8%

Since Revenue Growth is between 5 - 10, 2 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $52 M
Share Count 5 Years Ago (2020-12-31): $51 M

Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Earnings Per Share (EPS): $9.60
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0%

Since Dividend Per Share is less than or equal to 0, 0 point assigned.

Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Average ROE: 7%

Since Average ROE is less than 10, 1 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $149
52-Week Low: $92
Threshold Price (15% Above 52-Week Low): $106

Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $6,662 M

Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the calculated score, we recommend do not exceed 2% exposure of Total Portfolio.
Value-Trade has assigned 12 points to above Charles River Laboratories (CRL) stock.
Twenty Years Avg PE 22, Fair Value PE 12, Industry Based PE is 25 and Growth based PE is 10. Based on these all values average assigned is 17.25.
Value-Trades has assined P/E value 17.25. Since current year earning per share is $9.60.
The fair value of Charles River Laboratories (CRL) stock should be (17.25 x $9.60) = $165.6

Share this valuation:


Advertisement